Related Experiment Video

Updated: Sep 30, 2025

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

9.9K

The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment

Haoyue Hu1,2, Yue Chen3, Songtao Tan1

  • 1Lung Cancer Center, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, China.

Frontiers in Immunology
|March 14, 2022
PubMed

Insights

Anti-angiogenesis therapy combined with immunotherapy shows promise for solid tumors but faces resistance challenges. This review explores overcoming resistance and optimizing combination strategies for better cancer treatment outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Anti-angiogenesis therapy is a key cancer treatment strategy, but drug resistance, often linked to the tumor microenvironment, limits its efficacy.
  • Combining anti-angiogenesis drugs with immunotherapy has demonstrated synergistic antitumor effects in several solid tumors, including lung, liver, and kidney cancers.
  • However, this combination therapy shows unsatisfactory results in certain cancers like breast cancer, glioblastoma, and pancreatic ductal adenocarcinoma, highlighting unmet needs.

Purpose of the Study:

  • To review current anti-angiogenesis therapies and the mechanisms of drug resistance.
  • To discuss the intricate relationship between the tumor microenvironment and immunotherapy efficacy.
  • To evaluate the latest advancements in combining anti-angiogenesis therapy and immunotherapy for synergistic antitumor effects and explore new therapeutic strategies.

Main Methods:

  • Literature review of current anti-angiogenesis therapies and drug resistance mechanisms.
  • Analysis of the role of the tumor microenvironment in modulating immunotherapy response.
  • Synthesis of recent research on the combination of anti-angiogenesis therapy and immunotherapy.

Main Results:

  • Combination therapy is effective in specific solid tumors but faces challenges in others due to resistance.
  • Tumor microenvironment modulation is crucial for enhancing the efficacy of combined anti-angiogenesis and immunotherapy.
  • Lack of predictive biomarkers for resistance remains a significant hurdle.

Conclusions:

  • Combining anti-angiogenesis therapy with immunotherapy holds significant potential for synergistic antitumor effects.
  • Addressing drug resistance and understanding the tumor microenvironment are critical for optimizing this combination strategy.
  • Further research is needed to identify new targets and develop advanced therapeutic approaches for challenging tumors.
Keywords:
antiangiogenic therapycancer biologyimmune therapyprogresstumor microenvironment

More Related Videos

Isolation and Culture Expansion of Tumor-specific Endothelial Cells10:15

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

11.3K
Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice08:52

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

14.1K

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
702
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.0K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.8K